91 related articles for article (PubMed ID: 25964530)
21. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
22. Concentration-Induced J-Aggregate Formation Causes a Biphasic Change in the Release of trans-Combretastatin A4 Disodium Phosphate from Archaeosomes and the Subsequent Cytotoxicity on Mammary Cancer Cells.
Daswani VP; Ayesa U; Venegas B; Chong PL
Mol Pharm; 2015 Oct; 12(10):3724-34. PubMed ID: 26355665
[TBL] [Abstract][Full Text] [Related]
23. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
Liu L; Mason RP; Gimi B
Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
[TBL] [Abstract][Full Text] [Related]
24. Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions.
Feng D; Menger MD; Laschke MW
Fertil Steril; 2013 Nov; 100(5):1459-67. PubMed ID: 23993929
[TBL] [Abstract][Full Text] [Related]
25. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
26. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
27. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
Horsman MR; Ehrnrooth E; Ladekarl M; Overgaard J
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):895-8. PubMed ID: 9845117
[TBL] [Abstract][Full Text] [Related]
28. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
Anderson HL; Yap JT; Miller MP; Robbins A; Jones T; Price PM
J Clin Oncol; 2003 Aug; 21(15):2823-30. PubMed ID: 12807935
[TBL] [Abstract][Full Text] [Related]
29. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.
Welford AF; Biziato D; Coffelt SB; Nucera S; Fisher M; Pucci F; Di Serio C; Naldini L; De Palma M; Tozer GM; Lewis CE
J Clin Invest; 2011 May; 121(5):1969-73. PubMed ID: 21490397
[TBL] [Abstract][Full Text] [Related]
30. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
31. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
32. Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
Bertelsen LB; Bohn AB; Shen YY; Falborg L; Stødkilde-Jørgensen H; Horsman MR
BMC Cancer; 2014 Dec; 14():903. PubMed ID: 25466422
[TBL] [Abstract][Full Text] [Related]
33. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.
Xu XP; Wu XD; Liang GL; Huang WS; Wang L; Jing HY; Zhong SL
Pharmazie; 2012 Jun; 67(6):529-33. PubMed ID: 22822542
[TBL] [Abstract][Full Text] [Related]
35. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Ley CD; Kristjansen PE; Horsman MR
Acta Oncol; 2010 Oct; 49(7):906-13. PubMed ID: 20831477
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
[TBL] [Abstract][Full Text] [Related]
38. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of tumor angiogenesis by interferon-γ by suppression of tumor-associated macrophage differentiation.
Sun T; Yang Y; Luo X; Cheng Y; Zhang M; Wang K; Ge C
Oncol Res; 2014; 21(5):227-35. PubMed ID: 24854099
[TBL] [Abstract][Full Text] [Related]
40. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
Badn W; Kalliomäki S; Widegren B; Sjögren HO
Clin Cancer Res; 2006 Aug; 12(15):4714-9. PubMed ID: 16899622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]